Tesaro Inc. (TSRO) Given “Outperform” Rating at Leerink Swann
Leerink Swann reissued their outperform rating on shares of Tesaro Inc. (NASDAQ:TSRO) in a report published on Monday morning. They currently have a $115.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $108.00.
Other equities analysts have also recently issued reports about the stock. Robert W. Baird upped their target price on shares of Tesaro to $120.00 in a research note on Monday. Mizuho boosted their price target on shares of Tesaro from $67.00 to $94.00 and gave the company a buy rating in a report on Tuesday, July 5th. Citigroup Inc. boosted their price target on shares of Tesaro from $65.00 to $90.00 and gave the company a buy rating in a report on Friday, July 1st. Wedbush reissued a buy rating on shares of Tesaro in a report on Thursday, June 30th. Finally, FBR & Co reissued a buy rating on shares of Tesaro in a report on Thursday, June 30th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Tesaro has an average rating of Buy and an average price target of $109.76.
Tesaro (NASDAQ:TSRO) traded down 1.82% on Monday, hitting $115.76. 496,652 shares of the stock traded hands. The firm’s market cap is $5.95 billion. The stock has a 50-day moving average of $97.07 and a 200-day moving average of $69.78. Tesaro has a 12-month low of $29.51 and a 12-month high of $122.89.
Tesaro (NASDAQ:TSRO) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.71) by $0.43. The firm earned $36.60 million during the quarter, compared to analysts’ expectations of $4.98 million. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. During the same period in the prior year, the company earned ($1.51) EPS. Analysts forecast that Tesaro will post ($7.36) earnings per share for the current year.
In other news, SVP Martin H. Jr. Huber sold 408 shares of the firm’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $108.12, for a total transaction of $44,112.96. Following the completion of the transaction, the senior vice president now directly owns 1,250 shares of the company’s stock, valued at approximately $135,150. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Jeffrey H. Hanke sold 29,166 shares of the firm’s stock in a transaction that occurred on Tuesday, August 30th. The stock was sold at an average price of $86.04, for a total transaction of $2,509,442.64. Following the transaction, the vice president now directly owns 29,166 shares of the company’s stock, valued at $2,509,442.64. The disclosure for this sale can be found here. Insiders own 40.50% of the company’s stock.
Institutional investors have recently modified their holdings of the company. KCG Holdings Inc. acquired a new position in shares of Tesaro during the second quarter valued at $228,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Tesaro during the second quarter valued at $240,000. Bluestein R H & Co. acquired a new position in shares of Tesaro during the second quarter valued at $252,000. Neuberger Berman Group LLC acquired a new position in shares of Tesaro during the second quarter valued at $256,000. Finally, Amalgamated Bank acquired a new position in shares of Tesaro during the second quarter valued at $260,000. 88.81% of the stock is owned by institutional investors.
Tesaro Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Receive News & Stock Ratings for Tesaro Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tesaro Inc. and related stocks with our FREE daily email newsletter.